Pertuzumab: a novel humanized

mAb for the treatment of HER2

positive breast cancer.

Prepared by :
Md. Mominul Islam
ID # 162 1405 673
Breast Cancer Facts…

2nd position in case

of cancer deaths.

In every 13 minutes

1 woman will die.
Breast Cancer Prevalence in
Bangladesh
Approximately 1.5 lac
women die each year due
to cancer in Bangladesh.
WHO ranked
Bangladesh 2nd
position in mortality
rate of women
due to breast
cancer.
Types of Breast Cancer
HER-2 Positive Breast Cancer
 HER-2 Positive Breast Cancer

• HER-2 is a protein found on

the surface of normal
breast cells.

• Over expression of these

cells cause HER-2 positive
breast cancer

* HER-2 : Human Epidermal Growth factor receptor-2

 HER2-HER3 Dimerization
Most potent dimer in the development of HER2 positive breast
cancer
Treatment
Targeted Therapy-Pertuzumab

The HER2-HER3 dimerization inhibitor.

Pertuzumab, in combination with Trastuzumab

and Docetaxel, produces better results in
HER2 positive breast cancer.
Pertuzumab

A novel humanized monoclonal Antibody

It’s development for medical use began in1990

First Marketed as Perjeta by Genetech.

Pertuzumab Recommendations
Mode of Action
 Unique Features…
Selectively blocks the HER2 receptor
Only Pertuzumab Inhibits HER2-HER3
dimerization other than Trastuzumab &
Docetaxel.
In combination with Trastuzumab and
Docetaxel, produces better results in
HER2 positive breast cancer
No safety & efficacy limitations
observed with age
 Why better than existing Drugs?
Conventional treatment of HER2 positive breast
cancer Docetaxel and Trastuzumab blocks HER2-HER2
dimer only,

But
Unable to block the most potent HER2-HER3 dimer.
Where
Pertuzumab can.
Pertuzumab VS Trastuzumab with Docetaxel
for neoadjuvant therapy in HER2(+) BC.

Complete pathological response in %

Dose:
 Pertuzumab initially 840 mg,
46% followed by 420 mg for 3
weeks.

29%  Trastuzumab initially of 8

mg/kg, followed by 6 mg/kg
for 3 weeks
 Docetaxel 75-100mg/m2
every 3 weeks

** no. of patients 214

Pertuzumab+Trastuzumab Trsatuzumab+Docetaxel
+Docetaxel
Pertuzumab VS Trastuzumab with Docetaxel
in metastatic breast cancer.

Dose:
 Pertuzumab initially 840 mg,
followed by 420 mg for 3
weeks.
 Trastuzumab initially of 8
mg/kg, followed by 6 mg/kg
for 3 weeks
 Docetaxel 75-100mg/m2 every
3 weeks

* *No of patients 808

Pertuzumab+Gemcitabine Vs
Placebo+Gemcitabine in ovarian cancer treatment

Dose:
 Pertuzumab initially 840
mg, followed by 420 mg for
3 weeks.
 Gemcitabine 800 mg/m2
for 3 weeks
Prescribing Information
Indication:
Metastatic HER2 Breast Cancer, Neoadjuvant Treatment of
Breast Cancer
Dosage and Adminstration:
For intravenous infusion only.
Do not administer as an intravenous push or bolus.
The initial dose is 840 mg as a 60-minute IV infusion, followed
every 3 weeks thereafter by 420 mg as a 30 to 60 minute IV
infusion.
Precaution:
Special precautions should be taken in patients with cardiac
dysfunctions.
 Prescribing Information
Pregnancy Category D:
Pertuzumab is contraindicated in pregnancy.
During Lactation:
Breast feeding should be avoided during treatment with Pertuzumab.
Pediatric Use:
Safety and effectiveness of Pertuzumab have not been established in
pediatric patients.
Drug interactions:
Patients who receive anthracycline after receiving Pertuzumab maybe at
increased risk of cardiac dysfunction.
Contraindications:
Pertuzumab is contraindicated in patients with known hypersensitivity to
Pertuzumab or to any of its excipients.